Business Wire

Temenos Launches Industry’s First AI-Driven Buy-Now-Pay-Later Banking Service on the Temenos Banking Cloud

Share

Temenos (SIX: TEMN), the banking software company, today announced the launch of its Buy-Now-Pay-Later banking service. This offering will open up new revenue opportunities for banks and fintechs, help them reach new markets and cement their relationships with both consumers and merchants through alternative credit products.

Temenos BNPL, combined with patented Explainable AI, can help banks create ethically-driven lending programs by providing transparency into automated decisions and matching BNPL customers with appropriate credit offers based on their history.

As more consumers have turned to e-commerce amidst the pandemic, point-of-sale installment loans have grown in popularity and value. Consumer credit and installment loans have been revolutionized in the Banking-as-a-Service (BaaS) era by BNPL, which is seamlessly embedded into the customer buying journey to provide consumers a frictionless digital experience and easy access to finance at the point of sale. It also helps merchants improve retail customer acquisition, share of wallet, and retention. In 2021, online revenue through BNPL increased by 45% compared to 2019.1 McKinsey estimates fintechs have diverted up to $10bn in annual revenues away from banks over the past ~24 months with BNPL offerings.​2

BNPL provides significant advantages for both fintechs and banks. Fintechs benefit from rapid customer and merchant acquisition with relatively lower credit risk and more payments transactions. At the same time, banks can strengthen engagement with their customers, increase wallet share and loyalty by creating seamless, convenient purchasing experiences. BNPL can be profitable for incumbent banks that can build on their strengths, such as providing greater flexibility of loan terms and conditions and higher capital utilization due to faster loan turnover and lower regulatory capital requirements. Furthermore, BNPL presents cross-sell opportunities with potentially more engaged bank and non-bank customers.

The Temenos Buy-Now-Pay-Later banking service is independently consumable via the Temenos Banking Cloud. It’s agnostic of the underlying core banking system, being deployed alongside Temenos Transact or any other core banking solution and incorporates industry best practices while offering responsible lending capabilities to help providers adapt to evolving regulations. By offering the BNPL banking service, Temenos provides a fully flexible, pay-as-you-go solution that enables banks to rapidly introduce BNPL at scale without having to provision new IT infrastructure, so that they can focus on the customer experience.

By embedding XAI, Temenos enables clients to pre-approve loan applications or propose variable installments in real-time based on pre-determined criteria, including soft and hard credit scoring, while providing transparency into how decisions are made. This enables banks and fintechs to lend ethically, provide transparency into recommended payment schedules during the application process, and ensure that consumers can afford the repayments.

A global payments provider launched its Buy-Now-Pay-Later service on the Temenos Banking Cloud, growing to 22 million loan applications in just nine months, the fastest and most successful product launch in the company’s history. 70% of its customers are repeat users who love the product, with 50% using it again within three months.

Ginger Schmeltzer, Strategic Advisor, Retail Banking and Payments, Aite-Novarica Group: “Buy-Now-Pay-Later continues to grow in popularity, and this is reflected in increased adoption by retailers like Target and Amazon as well as a growing number of small and mid-sized merchants. The Temenos SaaS solution for BNPL, combined with embedded AI, brings together proven technology with increased speed, efficiency, scalability and decision-making transparency. Temenos’ robust and flexible BNPL as a Service will make this new business model available to companies of any size from the credit unions and the challengers, to global payments providers and Tier 1 banks.”

Max Chuard, Chief Executive Officer, Temenos, said: “In an extremely competitive market, financial services providers need to evaluate new business models to drive revenue. As the strategic technology provider for over 3,000 banks worldwide, we are committed to empowering our clients to pioneer and adopt those new, profitable business models. Buy-Now-Pay-Later has shown the industry that we can come up with new solutions to old problems. It has challenged the way we think about customer engagement, acquisition and retention. We are very excited to launch this new solution to enable our clients to offer alternative financing that is fast, seamless, and scalable.”

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.


1Holiday shopping 2021: 4 ways shoppers have changed since the pandemic began (cnbc.com)

2Buy now, pay later: Five business models to compete | McKinsey

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye